Anti-Mouse CD38 PE 200 ug
- Known as:
- Antibody toMouse CD38 PE 200 ug
- Catalog number:
- 12-0381-83
- Category:
- -
- Supplier:
- eBioscience
- Gene target:
- Anti-Mouse CD38 200
Related genes to: Anti-Mouse CD38 PE 200 ug
- Gene:
- CD38 NIH gene
- Name:
- CD38 molecule
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 4p15.32
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2014-11-18
Related products to: Anti-Mouse CD38 PE 200 ug
Related articles to: Anti-Mouse CD38 PE 200 ug
- Multiple myeloma (MM) is the second most prevalent hematologic malignancy worldwide. Proteasome inhibitors (PIs) are currently first-line clinical therapies, yet drug resistance has become a major challenge in clinical diagnosis and treatment. The invasiveness of bone marrow biopsies and the low sensitivity of serum monoclonal protein assays impede the early and precise assessment of proteasome inhibitors (PIs) resistance. Circulating MM cells (CMMCs) enable minimally invasive, dynamic monitoring of PI efficacy but are limited by insufficient sensitivity and specificity of current detection methods. In this study, an engineered and robust immunomagnetic nanoprobe (FeO@NH-MIL@CD138/CD38) was fabricated, by effectively loading magnetic FeO nanoparticles onto metal-organic framework nanorods (NH-MIL) functionalized with dual CD138 and CD38 antibodies. This nanoprobe created an efficient bio-interface to achieve high-efficiency CMMC capture within the range of 8~250 cells/300 μL. Using 1.0 mL peripheral blood from each patient, we captured CMMCs with the FeO4@NH-MIL@CD138/CD38 nanoprobe and systematically evaluated the correlations between CMMC counts and key clinicopathologic parameters and clinical therapeutic response to PIs in MM patients. CMMC counts were associated with MM clinical stages. Moreover, dynamic changes in CMMC counts measured by this nanoprobe can sensitively reflect responses to PIs therapy. Specifically, CMMC counts were elevated in nearly all patients with progressive disease and decreased in patients with a favorable treatment response. This work provides a potential index for real-time assessing MM disease progression and PIs treatment outcomes. - Source: PubMed
Publication date: 2026/07/20
Lai RanLi MengyiZhang HuanxinZou ShijiaoYan YueWu ShipingQiao YuxinCheng XinningWang TaoLi Chenglin - Functional high-risk (FHR) multiple myeloma (MM) was historically defined as progression within 18 months of starting therapy, with expected subsequent overall survival (OS) <2 years. The optimal definition of FHR in the era of combined quadruplet therapy (QUAD) + autologous stem cell transplantation (ASCT) is unknown. - Source: PubMed
Ravi GayathriDhakal BinodCallander Natalie SMedvedova EvaDholaria Bhagirathbhai RGodby Kelly NBal SusanHuls ForestSilbermann Rebecca WCosta Luciano J - Multiple myeloma is a hematological malignancy characterized by the uncontrolled proliferation of plasma cells within the bone marrow microenvironment. Despite significant progress in immunotherapy, particularly with CD38-targeted monoclonal antibodies, treatment resistance and disease relapse remain major clinical challenges. In this study, we develop a fractional-order mathematical model describing the interactions between healthy marrow cells, CD38-positive malignant plasma cells, and CD38-negative malignant cells associated with therapeutic resistance. The model incorporates immune-mediated tumor suppression and treatment-induced phenotypic switching mechanisms. The principal mathematical contribution is the formulation of a fractional-order CD38-mediated multiple myeloma model that combines immune interactions, therapy-induced phenotypic switching, and memory-dependent dynamics within a unified framework. To capture biological memory effects arising from cumulative therapy exposure and delayed immune responses, the system is formulated using the Caputo fractional derivative. The qualitative properties of the model are rigorously investigated. We establish the existence, uniqueness, positivity, and boundedness of solutions, ensuring biological feasibility of the system. A threshold quantity representing the effective reproductive capacity of malignant cells is derived and used to characterize the stability of equilibrium states. The analysis shows that the cancer-free equilibrium is globally stable when the threshold value remains below unity, while persistent tumor dynamics arise when it exceeds this critical level. Numerical simulations are carried out using the Atangana-Owolabi fractional numerical scheme and compared with fractional Adams-Bashforth and fractional Euler methods. Convergence analysis demonstrates improved numerical accuracy of the proposed approach. Computational experiments further reveal the influence of memory effects, immune clearance, and proliferation rates on tumor progression. The results highlight the importance of immune-mediated removal and targeted therapy in controlling malignant plasma cell populations and demonstrate the potential of fractional modeling for understanding complex tumor-immune-treatment interactions. - Source: PubMed
Publication date: 2026/07/19
Khirsariya Sagar RThakker ChintanNoori Noorullah - Adolescent girls and young women (AGYW) in South Africa experience a disproportionate burden of HIV infection. Genital inflammation has been implicated in increased HIV susceptibility through enhanced availability of target immune cells; however, the effects of recent sexual activity and vaginal-stimulating product (VSP) use on mucosal immune responses remain incompletely defined. This study characterised mucosal immune profiles following recent sexual exposure and VSP use in adolescent and adult women. HIV-negative sexually active adolescents (14-19 years) and adult women (25-35 years) were enrolled in a longitudinal cohort in KwaZulu-Natal, South Africa. Cervical cytobrush samples and cervicovaginal secretions were collected at baseline (≥ 2 weeks abstinence) and following reported sexual activity and/or VSP use. Cervical T-cell activation markers (CD38, HLA-DR, CCR5, α4β7) were quantified by flow cytometry, and 18 cytokines and chemokines were measured using a multiplex assay. Associations with time since last sexual intercourse were assessed using correlation analyses, and factors associated with genital inflammation were evaluated using weighted logistic regression. Recent sexual activity showed inverse associations with several pro-inflammatory cytokines, including MIP-1α, IL-1α, IL-1β, GM-CSF, and IL-17, consistent with a transient pattern of mucosal immune activation following exposure. In multivariable models, recent sexual activity (OR 0.58; p = 0.009) and bacterial vaginosis (OR 2.38; p = 0.017) were independently associated with genital inflammation, whereas VSP use was not statistically significant after adjustment (OR 1.63; p = 0.187). Although higher cytokine concentrations were observed among VSP users in unadjusted analyses, including IL-1α in adolescents (p = 0.001) and MIP-1α in adults (p = 0.017), these associations did not remain significant after correction for multiple testing. Overall, these findings suggest that recent sexual activity is associated with transient changes in mucosal immune mediators, while VSP use does not independently predict genital inflammation in this cohort after adjustment for confounding and multiple testing. These results highlight the importance of timing of exposure in interpreting mucosal immune measurements and support further longitudinal studies with precise sampling intervals to better define post-coital immune dynamics and the role of behavioural practices in shaping genital immunity. - Source: PubMed
Publication date: 2026/07/19
Radebe SamukelisiweRadebe PhumlaGumbi ZanenhlanhlaTanko Ramla FManhanzva MonalisaMntambo NtombenhleHumphries HiltonSamsunder NatashaLewis LaraLetsoalo MarothiMtshali AndileMzobe GugulethuPotloane DiseboMasson LindiPassmore Jo-Ann SJaspan Heather BSaruchera BesterKarim Quarraisha AbdoolNgcapu SinayeBunjun RubinaMkhize Pamela P - Antibody-mediated rejection (AMR) is a major cause of kidney transplant failure. The CD38 antibody felzartamab has been shown to reduce AMR activity, but recurrence after stopping treatment suggested a need for sustained therapy. We extended a placebo-controlled phase 2 trial (NCT05021484) to assess the feasibility and durability of prolonged, biomarker-guided treatment. - Source: PubMed
Publication date: 2026/07/09
Mayer Katharina ADiebold MatthiasSchrezenmeier Eva VHalloran Philip FHaindl SusanneSchatzl MartinaAkifova AylinAllmer Daniela MSchranz SabineKozakowski NicolasKläger JohannesAmann KerstinBeck JuliaSchütz EkkehardNaesens MaartenLoupy AlexandreRaynaud MarcGörzer IreneVietzen HannesIngle GordonFlesher Donna LPatel Uptal DHalleck FabianGraf IreneJilma BerndBudde KlemensBöhmig Georg A